GAN PLC (LON:GAN) Buy Rating Reconfirmed at Liberum Capital; With GBX 74.00 Target; Egalet (EGLT) Has 0.58 Sentiment

GAN PLC (LON:GAN) had its stock rating noted as Buy by analysts at Liberum Capital. Liberum Capital currently has a GBX 74.00 TP on the 22.28 million GBP market cap company or 138.71% upside potential. This was released in an analyst note on Monday morning.

Egalet Corporation, a specialty pharmaceutical company, develops, makes, and commercializes treatments for patients with pain and other conditions. The company has market cap of $44.72 million. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic moderate to severe pain where an opioid is appropriate; and ARYMO ER, an extended-release morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. It currently has negative earnings. The firm is also developing Egalet-002, a Guardian Technology AD, ER, oral oxycodone formulation, which is in Phase III clinical trials for the same indication as ARYMO ER.

Armistice Capital Llc holds 0.31% of its portfolio in Egalet Corporation for 2.05 million shares. New Jersey Better Educational Savings Trust owns 120,000 shares or 0.13% of their US portfolio. Moreover, Highbridge Capital Management Llc has 0.08% invested in the company for 4.25 million shares. The New Jersey-based Nj State Employees Deferred Compensation Plan has invested 0.08% in the stock. Sabby Management Llc, a New Jersey-based fund reported 721,050 shares.

Analysts await Egalet Corporation (NASDAQ:EGLT) to report earnings on March, 8. They expect $-0.38 EPS, up 56.32% or $0.49 from last year’s $-0.87 per share. After $-0.46 actual EPS reported by Egalet Corporation for the previous quarter, Wall Street now forecasts -17.39% EPS growth.

The stock decreased 3.70% or $0.04 during the last trading session, reaching $1.04. About 1.08M shares traded. Egalet Corporation (EGLT) has declined 46.67% since January 15, 2017 and is downtrending. It has underperformed by 63.37% the S&P500.

Among 2 analysts covering Gameaccount Network Plc (LON:GAN), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Gameaccount Network Plc has GBX 74 highest and GBX 64 lowest target. GBX 74’s average target is 132.70% above currents GBX 31.8 stock price. Gameaccount Network Plc had 8 analyst reports since August 24, 2016 according to SRatingsIntel. Liberum Capital maintained it with “Buy” rating and GBX 74 target in Monday, January 15 report. Goodbody maintained the stock with “Hold” rating in Wednesday, August 24 report. Liberum Capital maintained the stock with “Buy” rating in Friday, October 27 report. The stock of GAN plc (LON:GAN) earned “Hold” rating by Goodbody on Friday, September 30. Liberum Capital maintained the stock with “Buy” rating in Thursday, September 28 report. Goodbody maintained GAN plc (LON:GAN) on Monday, September 12 with “Hold” rating. On Friday, November 24 the stock rating was maintained by Liberum Capital with “Buy”.

GAN plc provides enterprise online gaming software, operational support services, and online game content development services to the casino industry. The company has market cap of 22.28 million GBP. The firm operates through Business to Business, and Business to Consumer divisions. It currently has negative earnings. It licenses GameSTACK, an Internet gaming system to online and land gaming operators for regulated real-money and simulated gaming online.